AURORA CANNABIS INC (ACB.CA) Stock Fundamental Analysis
TSX:ACB - CA05156X8504 - Common Stock
6.78 CAD
+0.09 (+1.35%)
Overall ACB gets a fundamental rating of 3 out of 10. We evaluated ACB against 35 industry peers in the Pharmaceuticals industry. ACB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ACB is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
ACB had negative earnings in the past year.
ACB had a positive operating cash flow in the past year.
ACB had negative earnings in 4 of the past 5 years.
ACB had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of ACB (-2.32%) is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -3.53%, ACB is in line with its industry, outperforming 60.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.32% | ||
| ROE | -3.53% | ||
| ROIC | N/A |
ROA(3y)-55.32%
ROA(5y)-62.11%
ROE(3y)-90.28%
ROE(5y)-91.51%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ACB has a worse Gross Margin (4.04%) than 77.14% of its industry peers.
In the last couple of years the Gross Margin of ACB has declined.
ACB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 4.04% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-29.39%
2. Health
2.1 Basic Checks
ACB does not have a ROIC to compare to the WACC, probably because it is not profitable.
ACB has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ACB has been reduced compared to 5 years ago.
ACB has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -9.40, we must say that ACB is in the distress zone and has some risk of bankruptcy.
ACB has a worse Altman-Z score (-9.40) than 85.71% of its industry peers.
A Debt/Equity ratio of 0.07 indicates that ACB is not too dependend on debt financing.
ACB has a Debt to Equity ratio of 0.07. This is in the better half of the industry: ACB outperforms 71.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -9.4 |
ROIC/WACCN/A
WACC9.37%
2.3 Liquidity
ACB has a Current Ratio of 2.97. This indicates that ACB is financially healthy and has no problem in meeting its short term obligations.
ACB has a better Current ratio (2.97) than 74.29% of its industry peers.
ACB has a Quick Ratio of 1.51. This is a normal value and indicates that ACB is financially healthy and should not expect problems in meeting its short term obligations.
ACB has a better Quick ratio (1.51) than 62.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.97 | ||
| Quick Ratio | 1.51 |
3. Growth
3.1 Past
ACB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.79%, which is quite impressive.
The Revenue has grown by 28.42% in the past year. This is a very strong growth!
ACB shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.94% yearly.
EPS 1Y (TTM)44.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-307.69%
Revenue 1Y (TTM)28.42%
Revenue growth 3Y11.86%
Revenue growth 5Y6.94%
Sales Q2Q%17.48%
3.2 Future
The Earnings Per Share is expected to grow by 103.58% on average over the next years. This is a very strong growth
ACB is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.42% yearly.
EPS Next Y-288.53%
EPS Next 2Y130.64%
EPS Next 3Y81.3%
EPS Next 5Y103.58%
Revenue Next Year8.72%
Revenue Next 2Y5.83%
Revenue Next 3Y6.05%
Revenue Next 5Y7.42%
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
ACB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 25.49, the valuation of ACB can be described as expensive.
Based on the Price/Forward Earnings ratio, ACB is valued a bit cheaper than the industry average as 77.14% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of ACB to the average of the S&P500 Index (22.69), we can say ACB is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 25.49 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as ACB's earnings are expected to grow with 81.30% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y130.64%
EPS Next 3Y81.3%
5. Dividend
5.1 Amount
No dividends for ACB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:ACB (9/5/2025, 7:00:00 PM)
6.78
+0.09 (+1.35%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners19.7%
Inst Owner ChangeN/A
Ins Owners0.05%
Ins Owner ChangeN/A
Market Cap381.38M
Analysts73.33
Price Target8.08 (19.17%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-321.48%
Min EPS beat(2)-426.74%
Max EPS beat(2)-216.23%
EPS beat(4)1
Avg EPS beat(4)935.07%
Min EPS beat(4)-426.74%
Max EPS beat(4)4494.06%
EPS beat(8)3
Avg EPS beat(8)450.07%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.04%
Min Revenue beat(2)-0.84%
Max Revenue beat(2)0.93%
Revenue beat(4)3
Avg Revenue beat(4)7.13%
Min Revenue beat(4)-0.84%
Max Revenue beat(4)14.66%
Revenue beat(8)6
Avg Revenue beat(8)3.86%
Revenue beat(12)7
Avg Revenue beat(12)2.68%
Revenue beat(16)9
Avg Revenue beat(16)2.74%
PT rev (1m)-14.23%
PT rev (3m)-23.06%
EPS NQ rev (1m)-67.44%
EPS NQ rev (3m)55.57%
EPS NY rev (1m)-127.78%
EPS NY rev (3m)-127.78%
Revenue NQ rev (1m)-1.52%
Revenue NQ rev (3m)10.44%
Revenue NY rev (1m)-1.54%
Revenue NY rev (3m)-2.5%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 25.49 | ||
| P/S | 1.07 | ||
| P/FCF | N/A | ||
| P/OCF | 20.45 | ||
| P/B | 0.69 | ||
| P/tB | 0.83 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.35
EYN/A
EPS(NY)0.27
Fwd EY3.92%
FCF(TTM)0
FCFYN/A
OCF(TTM)0.33
OCFY4.89%
SpS6.36
BVpS9.81
TBVpS8.2
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.32% | ||
| ROE | -3.53% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 4.04% | ||
| FCFM | N/A |
ROA(3y)-55.32%
ROA(5y)-62.11%
ROE(3y)-90.28%
ROE(5y)-91.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-29.39%
F-Score6
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 81.56% | ||
| Cap/Sales | 5.24% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.97 | ||
| Quick Ratio | 1.51 | ||
| Altman-Z | -9.4 |
F-Score6
WACC9.37%
ROIC/WACCN/A
Cap/Depr(3y)56.47%
Cap/Depr(5y)106.5%
Cap/Sales(3y)8.76%
Cap/Sales(5y)35.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-307.69%
EPS Next Y-288.53%
EPS Next 2Y130.64%
EPS Next 3Y81.3%
EPS Next 5Y103.58%
Revenue 1Y (TTM)28.42%
Revenue growth 3Y11.86%
Revenue growth 5Y6.94%
Sales Q2Q%17.48%
Revenue Next Year8.72%
Revenue Next 2Y5.83%
Revenue Next 3Y6.05%
Revenue Next 5Y7.42%
EBIT growth 1Y4.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year150.01%
EBIT Next 3Y29.77%
EBIT Next 5Y25.22%
FCF growth 1Y92.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y208.3%
OCF growth 3YN/A
OCF growth 5YN/A